Myriad Genetics (MYGN) Total Non-Current Liabilities (2010 - 2026)

Myriad Genetics (MYGN) has reported Total Non-Current Liabilities for 17 consecutive years, with $334.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 11.83% year-over-year to $334.6 million; the TTM figure through Mar 2026 stood at $334.6 million (up 11.83% YoY), while the FY2025 annual figure was $336.7 million, up 3.82% from the prior year.
• Total Non-Current Liabilities fell to $334.6 million in Q1 2026 per MYGN's latest filing, from $336.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $440.6 million in Q2 2023 and bottomed at $258.1 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $321.7 million across 5 years, with a median of $315.2 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slumped 39.54% — and 2023, when it surged 70.71%.
• Myriad Genetics' Total Non-Current Liabilities stood at $269.0 million in 2022, then grew by 17.17% to $315.2 million in 2023, then advanced by 2.89% to $324.3 million in 2024, then increased by 3.82% to $336.7 million in 2025, then decreased by 0.62% to $334.6 million in 2026.
• Business Quant data shows MYGN's Total Non-Current Liabilities at $334.6 million in Q1 2026, $336.7 million in Q4 2025, and $353.6 million in Q3 2025.